Why the study?
Does nicardipine improve the treatment of systemic hypertension compared to placebo or other antihypertensive agents in patients with systemic hypertension?
Does nicardipine improve the treatment of systemic hypertension compared to placebo or other antihypertensive agents in patients with systemic hypertension?
Nicardipine is an effective calcium antagonist for systemic hypertension with a favorable safety profile regarding myocardial contractility and conduction.
Supports nicardipine for hypertension; leaves open its role versus contemporary agents in updated trials.
A new generation of dihydropyridine calcium antagonists which are related structurally to nifedipine is undergoing clinical investigation. Among these newer agents. nicardipine and nimodipine have become available for clinical use. In controlled trials, nicardipine is superior to placebo and equal to other antihypertensive agents for the treatment of systemic hypertension. Nicardipine is associated with a low incidence of adverse effects that are related primarily to its peripheral vasodilatory actions. In addition, nicardipine appears to have little if any negative effects on myocardial contractility or conduction.
No takes yet. Share an insight, caveat, or question.
William H. Frishman (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: